Young-Dong Severance Hospital
Welcome,         Profile    Billing    Logout  
 35 Trials 
19 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Jae-Hoon
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, Japan, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NCT06730347: A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Not yet recruiting
2
60
Canada, US, RoW
Lorigerlimab, MGD019
MacroGenics
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer
02/27
08/27
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
Kim, Jae Weon
NCT04655482: Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Recruiting
4
30
RoW
Aflibercept Injection, Intravitreal injection of aflibercept (Eylea, Bayer co.)
Kim's Eye Hospital, Bayer
Retinal Angiomatous Proliferation
12/23
08/24
NCT04840550: Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs

Recruiting
3
390
RoW
Lansoprazole 15 mg, Tegoprazan 25 mg
HK inno.N Corporation
Preventive Peptic Ulcer
06/24
07/24
RODIN, NCT05041010: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Recruiting
3
496
RoW
Neu2000KWL group, Placebo group
GNT Pharma
Ischemic Stroke
06/24
01/25
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
VISUALIZE, NCT06145048: Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Completed
2
89
US, RoW
VGT-309
Vergent Bioscience, Inc.
Lung Cancer, Lung Metastases
10/24
02/25
EB-203-201, NCT06487039: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

Recruiting
2
50
RoW
EB-203
EyebioKorea, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
08/25
01/26
NCT05933031: Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

Recruiting
2
381
RoW
Tegoprazan 50 mg Triple Therapy, Tegoprazan 100 mg Triple Therapy, Lansoprazole Triple Therapy
HK inno.N Corporation
Helicobacter Pylori Infection
12/24
12/24
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Recruiting
2
150
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Diabetic Macular Edema (DME)
11/25
12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Recruiting
2
180
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
11/25
12/25
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

Active, not recruiting
2
464
Europe, RoW
Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo
Chiesi Farmaceutici S.p.A.
Uncontrolled Asthma
03/26
02/27
NCT05509543: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

Completed
1
60
RoW
IY-NT-T, IY-NT-R, Noltec(the brand name)
Il-Yang Pharm. Co., Ltd.
Pharmacokinetics
10/22
12/23
NCT05729386: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

Recruiting
1
34
RoW
GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
GC Biopharma Corp
Healthy Volunteers
04/23
04/23
NCT05703984: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

Recruiting
1
50
RoW
GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
GC Biopharma Corp
Healthy Volunteers
04/23
04/23
NCT05617651: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

Not yet recruiting
1
50
RoW
IY-NT-T, IY-NT-R, Noltec(the brand name)
Il-Yang Pharm. Co., Ltd.
Pharmacokinetics
12/24
12/25
NCT05525949: Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke

Completed
N/A
93
RoW
VIVID Brain, No-treatment Control
Nunaps Inc
Visual Fields Hemianopsia, Hemianopsia, Homonymous
08/23
11/23
NCT06406439: DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

Active, not recruiting
N/A
120
RoW
Smart Insulin Pen, DIA:CONN P8
G2e Co., Ltd
Diabetes Mellitus
04/25
05/25
Park, Noh Hyun
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Jae-Hoon
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, Japan, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NCT06730347: A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Not yet recruiting
2
60
Canada, US, RoW
Lorigerlimab, MGD019
MacroGenics
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer
02/27
08/27
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
Kim, Jae Weon
NCT04655482: Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Recruiting
4
30
RoW
Aflibercept Injection, Intravitreal injection of aflibercept (Eylea, Bayer co.)
Kim's Eye Hospital, Bayer
Retinal Angiomatous Proliferation
12/23
08/24
NCT04840550: Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs

Recruiting
3
390
RoW
Lansoprazole 15 mg, Tegoprazan 25 mg
HK inno.N Corporation
Preventive Peptic Ulcer
06/24
07/24
RODIN, NCT05041010: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Recruiting
3
496
RoW
Neu2000KWL group, Placebo group
GNT Pharma
Ischemic Stroke
06/24
01/25
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
VISUALIZE, NCT06145048: Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Completed
2
89
US, RoW
VGT-309
Vergent Bioscience, Inc.
Lung Cancer, Lung Metastases
10/24
02/25
EB-203-201, NCT06487039: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

Recruiting
2
50
RoW
EB-203
EyebioKorea, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
08/25
01/26
NCT05933031: Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

Recruiting
2
381
RoW
Tegoprazan 50 mg Triple Therapy, Tegoprazan 100 mg Triple Therapy, Lansoprazole Triple Therapy
HK inno.N Corporation
Helicobacter Pylori Infection
12/24
12/24
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Recruiting
2
150
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Diabetic Macular Edema (DME)
11/25
12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Recruiting
2
180
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
11/25
12/25
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

Active, not recruiting
2
464
Europe, RoW
Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo
Chiesi Farmaceutici S.p.A.
Uncontrolled Asthma
03/26
02/27
NCT05509543: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

Completed
1
60
RoW
IY-NT-T, IY-NT-R, Noltec(the brand name)
Il-Yang Pharm. Co., Ltd.
Pharmacokinetics
10/22
12/23
NCT05729386: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

Recruiting
1
34
RoW
GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
GC Biopharma Corp
Healthy Volunteers
04/23
04/23
NCT05703984: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

Recruiting
1
50
RoW
GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
GC Biopharma Corp
Healthy Volunteers
04/23
04/23
NCT05617651: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

Not yet recruiting
1
50
RoW
IY-NT-T, IY-NT-R, Noltec(the brand name)
Il-Yang Pharm. Co., Ltd.
Pharmacokinetics
12/24
12/25
NCT05525949: Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke

Completed
N/A
93
RoW
VIVID Brain, No-treatment Control
Nunaps Inc
Visual Fields Hemianopsia, Hemianopsia, Homonymous
08/23
11/23
NCT06406439: DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

Active, not recruiting
N/A
120
RoW
Smart Insulin Pen, DIA:CONN P8
G2e Co., Ltd
Diabetes Mellitus
04/25
05/25
Park, Noh Hyun
No trials found

Download Options